24,446 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Acquired by Virtu Financial LLC

Virtu Financial LLC acquired a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,446 shares of the company’s stock, valued at approximately $30,000. Virtu Financial LLC owned about 0.05% of Shattuck Labs as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Atom Investors LP bought a new position in shares of Shattuck Labs in the third quarter worth about $35,000. Readystate Asset Management LP purchased a new stake in Shattuck Labs in the 3rd quarter valued at about $39,000. Benjamin Edwards Inc. bought a new position in Shattuck Labs in the 3rd quarter worth about $61,000. MetLife Investment Management LLC increased its position in shares of Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after acquiring an additional 13,859 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Shattuck Labs by 63.2% during the third quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after acquiring an additional 10,667 shares in the last quarter. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

STTK stock opened at $0.85 on Wednesday. The firm has a 50-day simple moving average of $1.23 and a two-hundred day simple moving average of $1.42. Shattuck Labs, Inc. has a one year low of $0.85 and a one year high of $11.76. The firm has a market cap of $40.38 million, a price-to-earnings ratio of -0.55 and a beta of 1.66.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, equities analysts predict that Shattuck Labs, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on STTK. Leerink Partners started coverage on Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Shattuck Labs in a report on Thursday, March 27th. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.